Healthcare
Live Price
Offline$33.37
+2.80% today
1Y Change
+76.28%
Window
Jun 20, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rigel Pharmaceuticals, Inc. (RIGL) is a Healthcare stock with a market cap of $540.00M and listed on NASDAQ. The stock last traded around $33.37 and up 76.3% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +64.1%, EPS growth of +1960.6%, a dividend yield of 0.0%. What stands out right now is revenue +64.1%, EPS +1960.6%, free cash flow +143.5% with operating margin 42.6% and ROIC 28.2%. Valuation is more restrained than many high-expectation growth names at P/E 1.4 and price/sales 1.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines RIGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RIGL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RIGL Max Drawdown
-50.08%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RIGL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$149.2M
+24.1% YoY
FY Net Income
-$17.9M
+69.4% YoY
Free Cash Flow
$5.3M
+107.1% YoY
Revenue Growth
+64.1%
EPS Growth
+1960.6%
Gross Margin
93.3%
Net Margin
124.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 294M | 179M | 117M | 120M | 149M |
| Gross Profit | 275M | 161M | 110M | 118M | 148M |
| Operating Income | 125M | 24M | -20M | -56M | -12M |
| EBITDA | 128M | 29M | -17M | -54M | -11M |
| Net Income | 367M | 17M | -25M | -59M | -18M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41M | 57M | 33M | 24M | 19M |
| Total Assets | 514M | 164M | 117M | 134M | 167M |
| Total Liabilities | 122M | 161M | 146M | 148M | 137M |
| Shareholder Equity | 391M | 3M | -29M | -14M | 30M |
| Total Debt | 53M | 60M | 61M | 42M | 31M |
| Net Debt | 13M | 3M | 28M | 17M | 12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+108.0% YoY
Capital Expenditures
627K
-39.3% YoY
Free Cash Flow
5M
+107.1% YoY
Key ratios
Gross Margin
93.3%
Operating Margin
42.6%
Net Margin
124.7%
ROE
240.8%
Debt / Equity
0.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.